Home4016 • TADAWUL
add
Middle East Pharmaceutical Inds Co SJSC
Previous close
SAR 125.00
Year range
SAR 90.20 - SAR 197.60
Market cap
2.50B SAR
Avg Volume
36.93K
P/E ratio
-
Dividend yield
-
Primary exchange
TADAWUL
Market news
Financials
Income Statement
Revenue
Net income
| (SAR) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 81.06M | 33.43% |
Operating expense | 40.29M | 44.14% |
Net income | 3.87M | 34.44% |
Net profit margin | 4.77 | 0.85% |
Earnings per share | — | — |
EBITDA | 9.20M | 16.59% |
Effective tax rate | 29.59% | — |
Balance Sheet
Total assets
Total liabilities
| (SAR) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 13.80M | — |
Total assets | 494.04M | — |
Total liabilities | 167.85M | — |
Total equity | 326.19M | — |
Shares outstanding | 20.00M | — |
Price to book | 7.66 | — |
Return on assets | 3.33% | — |
Return on capital | 4.17% | — |
Cash Flow
Net change in cash
| (SAR) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 3.87M | 34.44% |
Cash from operations | -29.50M | -320.16% |
Cash from investing | -3.92M | 33.73% |
Cash from financing | 25.59M | 390.11% |
Net change in cash | -7.83M | -484.48% |
Free cash flow | -39.07M | — |
About
Founded
1998
Headquarters
Website
Employees
543
